INSILICO (03696) rose more than 6%, reaching a high of HK$62.9 to set a new record since its listing. As of the time of writing, the stock was up 6.11% to HK$62.5, with a turnover of HK$26.3799 million. The company announced that the Investigational New Drug (IND) application for its oral NLRP3 inhibitor, ISM8969, intended for the treatment of inflammatory and neurodegenerative diseases, has been approved by the U.S. Food and Drug Administration (FDA) for Parkinson's disease treatment. The upcoming Phase I clinical study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM8969 in healthy subjects and to determine the clinically recommended optimal dose for further subsequent research. Notably, to accelerate the global development of ISM8969, INSILICO has entered into a co-development collaboration agreement with Hengtai Biotech. Both parties hold 50% of the global rights to this project, and INSILICO is eligible to receive upfront and milestone payments totaling up to over HK$500 million. Furthermore, INSILICO recently released its large language model training framework, Science MMAI Gym, which aims to transform LLMs with causal reasoning capabilities into high-performance engines capable of handling real-world drug discovery and development tasks. After training, LLMs that previously had failure rates as high as 75%–95% in specialized task areas can achieve up to a 10-fold performance improvement in key drug discovery benchmarks. This release is set to further advance the vision of Pharmaceutical Super Intelligence (PSI).